|View printer-friendly version|
|Vitae Pharmaceuticals Appoints Dr. John M. Leonard to Board of Directors|
"We are pleased to welcome John to Vitae's board and look forward to benefiting from his breadth of R&D and drug development expertise," said
Since 2014, Dr. Leonard has served as the Chief Medical Officer of Intellia Therapeutics, a privately held biotechnology company active in gene therapy utilizing CRISPR/Cas9. He is also an Executive Partner at
Dr. Leonard has extensive experience in senior research and leadership roles in the biopharmaceutical industry. From 1992 to 2008, Dr. Leonard held various positions in Abbott's
"I am eager to lend my experience to help Vitae deliver promising therapies for difficult-to-drug targets in disease areas with significant unmet needs," commented Dr. Leonard. "The Company's RORγt inhibitor for autoimmune disorders and LXR agonist for atopic dermatitis have the potential to be first-in-class or best-in-class treatments for patients."
Dr. Leonard currently serves on the boards of
For additional information, please visit the company's website at www.vitaepharma.com.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Vitae's product candidates. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "anticipate," "project," "target," "design," "estimate," "predict," "potential," "plan," "impending" or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward- looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vitae is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Vitae's forward-looking statements include, among others, the timing and success of preclinical studies and clinical trials conducted by Vitae and its collaborative partners; the ability to obtain and maintain regulatory approval of Vitae's product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing Vitae's product candidates; the size and growth of the potential markets for Vitae's product candidates and the ability to serve those markets; Vitae's expectations regarding Vitae's expenses and revenue, the sufficiency of Vitae's cash resources and needs for additional financing; Vitae's ability to attract or retain key personnel; and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vitae's Annual Report on Form 10-K for the year ended